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Abstract
Background: Magnetic resonance imaging (MRI) is a promising tool for monitoring stem cell-based therapy. Conventionally,
cells loaded with ironoxide nanoparticles appear hypointense on MR images. However, the contrast generated by ironoxide
labeled cells is neither specific due to ambiguous background nor quantitative. A strategy to overcome these drawbacks is
19F MRI of cells labeled with perfluorocarbons. We show here for the first time that human neural stem cells (NSCs), a
promising candidate for clinical translation of stem cell-based therapy of the brain, can be labeled with
19F as well as
detected and quantified in vitro and after brain implantation.
Methodology/Principal Findings: Human NSCs were labeled with perfluoropolyether (PFPE). Labeling efficacy was assessed
with
19F MR spectroscopy, influence of the label on cell phenotypes studied by immunocytochemistry. For in vitro MRI, NSCs
were suspended in gelatin at varying densities. For in vivo experiments, labeled NSCs were implanted into the striatum of
mice. A decrease of cell viability was observed directly after incubation with PFPE, which re-normalized after 7 days in
culture of the replated cells. No label-related changes in the numbers of Ki67, nestin, GFAP, or bIII-tubulin+ cells were
detected, both in vitro and on histological sections. We found that 1,000 NSCs were needed to accumulate in one image
voxel to generate significant signal-to-noise ratio in vitro. A detection limit of ,10,000 cells was found in vivo. The location
and density of human cells (hunu+) on histological sections correlated well with observations in the
19F MR images.
Conclusion/Significance: Our results show that NSCs can be efficiently labeled with
19F with little effects on viability or
proliferation and differentiation capacity. We show for the first time that
19F MRI can be utilized for tracking human NSCs in
brain implantation studies, which ultimately aim for restoring loss of function after acute and neurodegenerative disorders.
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Introduction
To achieve translation of experimental stem cell-based therapy
into the clinic, non-invasive imaging modalities are necessary tools.
One such modality, magnetic resonance imaging (MRI), provides
true three-dimensional data at high spatial resolution, enabling
good detection of even small cell numbers in the living, intact
individual. Commonly, contrast is achieved through in vitro
labeling of cells with superparamagnetic iron oxide (SPIO)
nanoparticles [1,2,3]. Although even single cells can be detected
[4] with this procedure, the contrast generated by iron oxide
labeled cells can easily be confounded with other sources such as
bleedings or blood vessels [5]. Furthermore, since contrast is
achieved indirectly through disturbances of the local magnetic
field experienced by surrounding hydrogen nuclei, quantification
of the number of cells in vivo is questionable [6].
A rapidly emerging field to overcome these drawbacks of
ambiguity of contrast assignment and cell quantification is cell
labeling with perfluorocarbon (PFC) nano-emulsions, which can
be detected with
19F MRI [7,8,9]. The
19F nucleus is particularly
suitable for labeling as its relative MR sensitivity is only 17% less
than that of
1H. Furthermore, the signal intensity is directly
proportional to the number of accumulated
19F, hence, allowing in
vivo quantification of
19F labeled cells [10]. In addition, since the
level of background
19F signal in host tissue is virtually absent [10],
overlaying the
19F image on an anatomical
1H image allows for
unambiguous, quantitative tracking of labeled cells in vivo.
However, compared to labeling and tracking with metal-based
contrast agents the technique is considerably less sensitive
requiring a large amount of
19F to accumulate in order to
generate sufficient signal-to-noise ratio (SNR).
The strategy of
19F cell labeling has already been applied to
monitor cells during pathological conditions, e.g. umbilical cord
blood cell localization in tumor-bearing mice [11], T-cell
migration in murine models of diabetes [12], and local
inflammation [13]. More recently, PFCs have proven useful in
19F MRI studies of inflammatory response to cerebral and cardiac
ischemia [14] and in vivo measurements of intracellular pO2 of
glioblastoma cells in response to chemotherapy [15].
In experimental models of human neurodegenerative diseases
cell therapies have shown that neuronal replacement and partial
repair of damaged brain circuitry is possible [16]. For a successful
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8clinical translation, only cells of human origin will be needed, and
one source of human cells are neural stem cells (NSCs) [17]. NSCs
derived from the human fetal striatum have been expanded with
both maintained normal karyotype and high capacity to generate
different neuronal phenotypes for a long time in vitro [18,19]. Upon
implantation, these cells survived in the stroke-damaged rat
striatum, migrated towards the injury, and differentiated into
mature neurons without tumor formation [18].
Since these cells represent a relevant cell source for clinical
translation, the purpose of the present study was to establish a
platform to visualize NSCs in vivo after intracerebral implantation
with
19F MRI. Monitoring the spatio-temporal dynamics of
NSCs grafted into the brain requires the ability to detect even
low cell numbers with high spatial resolution, since pathology-
related migration processes of interest may take place on a small
scale, the graft size may be diluted due to these processes or be
initially relatively small. A first report has already indicated that
it is feasible to detect fluorine labeled, immortalized, murine
neural progenitor cells in the healthy mouse brain with
19FM R I
[20]. The current study is the first to show that these results can
be extended to the tracking of human NSCs. Novelties of our
experiments compared to the previous studies on
19FM R Io f
stem cells [11,20] include i) the use of a clinically relevant source
of neural stem cells and detection with in vivo
19F MRI in a proof-
of-concept, ii) a conservative estimate of cell detection limits for
preclinical
19F MRI studies of neural stem cell implantation, and
iii) a careful assessment of potential adverse effects of the
19F
marker on cell viability and function both in vitro and in vivo over
a period of at least one week. We show that under optimized
preclinical conditions low numbers of cells can be detected in vivo
at good resolution and within acceptable scan time. Our results
suggest that
19F MRI may prove useful in monitoring implanted
cells in models of neurodegeneration, thus allowing the
optimization of preclinical protocols of graft induced brain
repair.
Materials and Methods
Culturing of human neural stem cells
NSCs were obtained from the ganglionic eminences of an 8-
week old aborted human fetus from Malmo ¨/Lund University
Hospitals, according to the guidelines approved by the Lund/
Malmo ¨ Ethical Committee. The full characterization of these
NSCs, derived from the human fetal striatum, has previously been
described in detail [19]. Briefly, after microdissection and
dissociation of the striatal tissue, cells were maintained at 37uC
in a humidified atmosphere with 5% CO2. The neurosphere
expansion medium (DMEM/F-12, Gibco, Grand Island, USA; L-
glutamine, 2.92 g/100 mL; HEPES, 23.8 mg/100 mL; NaHCO3,
7.5%; glucose, 0.6%; and heparin, 2%, all from Sigma–Aldrich,
Hamburg, Germany) contained N-2 supplement (1%, Gibco),
human leukemia inhibitory factor (10 ng/mL, Sigma–Aldrich),
epidermal growth factor, 20 ng/mL and fibroblast growth factor,
10 ng/mL (both from Peprotech, Hamburg, Germany).
Labeling cells with
19F marker and determination of
intracellular
19F content
A few hours prior to labeling, the small neurospheres were
transferred to a Poly(2-hydroxyethyl methacrylate) (Poly-HEMA,
Sigma-Aldrich) coated culture flask, in order to avoid strong
attachment of the cells as a consequence of the label. We
incubated cells with 5 mL, 15 mL, 50 mL, 100 mL, and 150 mLo fa
perfluoropolyether (PFPE) nano-emulsion (CELSENSE 1000,
Celsense, Pittsburg, USA, 120 mg PFPE/ml, experimentally
determined concentration of magnetically equivalent
19Fc =
3.11 M)/mL culture medium to determine the optimal concen-
tration in terms of fluorine uptake. In the end the emulsion was
added at the empirically determined optimal (see Results)
concentration of 100 ml/mL medium 3 days after the last
passage directly to the NSC culture medium and cells were
incubated for 36 hours. Subsequently, the cell suspension was
spun down at 1846 g for 5 min, the pellet was washed twice
and finally resuspended in either fresh medium or potassium
phosphate-buffered saline (KPBS) or Hank’s Balanced Salt
Solution (HBSS), depending on the application.
In order to determine the amount of intracellular
19F, 10 mlo fa
solution containing 10 mg KF/mL H2O (i.e. 1.04*10
18 19F spins)
was added as an internal fluorine reference to the sample, which
was then scanned with magnetic resonance spectroscopy (MRS,
see below). The amount of fluorine was determined by comparing
the integrated area of the PFPE main peak and the KF reference
peak in the
19F MR spectra.
Determination of in vitro cell detectability
To determine the limits of in vitro detectability with MRI, the
19F
labeled, small neurospheres were spun down, washed in KPBS,
fixed with 4% paraformaldehyde (PFA), washed again and
resuspended in KPBS. The fixed, labeled neurospheres were
either transferred to small tubes or injected at different cell
concentrations into phantoms made of 2% gelatin in small,
custom-made cups 22 mm in diameter for subsequent scans with
MRI.
Assessment of label influence on cell viability,
proliferation and differentiation
Cell viability was determined in culture by trypan blue exclusion
method before, shortly after, and at 7 days after labeling, and
compared to unlabeled control cultures. Experiments were
performed in triplicates. For determination of the cell phenotypes
within the proliferating culture,
19F labeled neurospheres were
plated on PLL coated 8-well chamber slides, allowed to attach for
3 h, then fixed and processed for immunocytochemistry. For
determination of cell differentiation capacity, growth factors were
removed and 1% fetal bovine serum (Gibco) was added. Labeled
cells were differentiated for 9 days, then fixed and subsequently
stained. Medium was changed every third day during experiments.
Animal experiments
All experiments were conducted according to the guidelines laid
out in the German Animal Welfare Act and approved by the local
authorities (Landesamt fu ¨r Natur, Umwelt und Verbraucherschutz
Nordrhein-Westfalen) under permission number 9.93.2.10.
31.07.048 (dated 22 May 2007). Four adult male CD 1 mice
(bodyweight 37–42 g, Janvier, Le Genest Saint Isle, France) were
used for the cell implantation and
19F MRI investigations. All
experiments were performed under anesthesia. Animals were
housed in cages under a 12 h light/12 h darkness cycle with access
to food and water ad libitum.
Implantation procedures
Human NSC cultures (passage 14) were labeled with
19F marker
as stated above. At the day of implantation,
19F labeled
neurospheres (diameter<100 mm) were centrifuged and resus-
pended in HBSS (Gibco). The neurosphere suspension had a
concentration of approximately 100,000 viable cells/mL and was
kept on ice during the whole procedure. Mice were anesthetized
with 1–2% isoflurane in a 70/30 nitrous oxide/oxygen mixture
19F MRI of Human Neural Stem Cells
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maintained the body temperature at 37uC (medres, Cologne,
Germany). The non-labeled and
19F labeled neurosphere
suspensions were injected using a Hamilton syringe into two
deposits per hemisphere into the striatum (1.5 mL i.e. 150,000 cells
per deposit) in two animals. Two further animals were injected
bilaterally with two deposits of
19F labeled cells on the left and one
deposit on the right hemisphere. The following coordinates were
used: AP, +1.0, ML, 62.0 mm from bregma, and DV, 23.0 and
22.0 mm from the brain surface. After each deposit, the needle
was kept in place for 5 min before slow withdrawal. The wound
was closed with suture and animals were allowed to recover in
their cages. To suppress an immune reaction, animals received a
subcutaneous injection of 20 mg/kg Cyclosporine A (Sigma-
Aldrich) every second day starting 2 days before implantation.
MRI acquisition
MRI and MRS were carried out on a Biospec 11.7 T/16 cm
dedicated animal scanner system (Bruker BioSpin, Ettlingen,
Germany) equipped with actively shielded gradient coils (BGA9S,
750 mT m
21, Bruker BioSpin). For radiofrequency transmission
and reception, we used custom-built, inductively coupled, single-
loop surface coils of 9 mm diameter for in vitro MRS, 25 mm
diameter for in vitro MRI, and 20 mm diameter for in vivo MRI, all
tunable from 470 MHz for the




19F MRS: For the in vitro quantification of
19F content
with MRS, we used a spin-density weighted pulse-acquire
spectroscopic sequence with short acquisition delay of 0.05 ms,
and with long repetition time (TR) of 20 s to assure full relaxation
recovery (90u rectangular hard pulse, duration/bandwidth
(BW)=0.01 ms/128 kHz, 163.8 ms acquisition window, spectral
points/BW=8192/50 kHz). We chose the number of averages
(NA) dependent on the strength of PFPE signal, with typically
NA=30, leading to an acquisition time (TA)=10 min. All
measured
19F concentrations are presented with respect to the
main PFPE frequency (293.2 ppm), i.e. the chemical shift signal
originating from the end group of the PFPE molecule was not
taken into account.
Determination of relaxation times: To optimize sequence
parameters, the relaxation times were measured with the 9 mm
coil on a tube containing either the pure PFPE marker or the
labeled cells. The temperature was kept at 37u throughout the
experiment with a feedback controlled water system (medres). T1
was measured with a pulse-acquire saturation-recovery sequence
(20 experiments, TR=90.3 ms up to 20 s, pulse identical to in
vitro, 66.7 ms acquisition window, spectral points/BW=1000/
15 kHz), T2 with a multi spin echo sequence (TR=4 s, echo
spacing 20 ms, field of view (FOV)=1661662.5 mm
3,3 2 632
matrix, 15 echoes, NA=4 (PFPE)/100 (cells), TA=4 min/
3:33 h). The spectral peak area or the signal in the multi-echo
images S were then fitted with the software Origin (OriginLab
Corporation, Northhampton, USA) to the function S~S0
1{exp({TR=T1) ðÞ for T1 or S~S0 exp({TE=T2) for T2, with
the equilibrium signal S0.
In vivo
19F MRS: MRS was performed to determine the exact
PFPE frequency in vivo using a pulse-acquire sequence identical to
the in vitro experiments but with shorter TR (30u pulse,
TR=200 ms, NA=3,000, TA=10 min).




performed with a turbo spin echo sequence (TR/effective echo
time (TEeff)=2200 ms/42.8 ms, 8 echoes per excitation, NA=2,
10 consecutive, 1 mm thick slices, FOV=1.9261.92 cm
2,
1286128 matrix, i.e. a resolution of 150615061000 mm
3,
TA=1 min, BW=50 kHz, linear phase encoding scheme) [21].
19F images were acquired with the same sequence and matching
geometry, but at lower in-plane resolution and lower BW
(NA=256, 48648 matrix, i.e. a resolution of 40064006
1000 mm
3, TA=57 min, BW=10 kHz). The transmission power
needed for a 90u pulse was determined on the
1H channel on a
1 mm thick slice parallel to the coil through the
19F labeled cells
and the same power was used after switching to the
19F frequency.
Approximately the same power is needed for the
1H and the
19F
90u pulse, which we tested on a combined
1H/
19F standard
(diluted Trifluoroaceticacid, data not shown).
In vivo measurement protocol: In vivo
19F and
1H imaging was
carried out 2 d after implantation for those mice that received
non-labeled control cells, and 2 d and 6 d after implantation for
the animals that were injected with labeled cells in both
hemispheres. Mice were anesthetized with an intraperitoneal
injection of a ketamine (120 mg/kg) and xylazine (8 mg/kg)
mixture to avoid background signal from fluorinated inhalation of
anesthesia gases. Anesthesia time was prolonged by subcutaneous
administration of 30–60 mg/kg ketamine at 1 h after induction.
Respiration rate was monitored using a pressure sensitive pad
placed under the thorax, together with DASYlab (Measurement
Computing, Norton, USA) software and body temperature was
maintained at 37uC with an in-house feedback controlled system.
Animals were fixed with ear bars in standard animal holders




MRI. The total time of the imaging session did not exceed 1.5 h.
Immunocytochemistry/immunohistochemistry
After the last MRI session, animals were deeply anesthetized
and perfused transcardially with saline followed by 4% PFA.
Brains were post-fixed overnight and then kept in 20% sucrose
solution until they sunk. Thirty micrometer thick sections were cut
in the coronal plane using a freezing microtome (Leica Micro-
systems, Wetzlar, Germany), and kept at 220uC in cryo-protective
solution. Cells were fixed in 4% PFA for 15 min at room
temperature followed by three rinses in KPBS. Before immuno-
staining, cells and tissue sections were pre-incubated in 5% normal
serum, and 0.025% and 0.25% Triton X-100, respectively, in
KPBS for 45 min at room temperature. Incubation in primary
antiserum was carried out overnight at +4uC and the following
primary antibodies were used: mouse anti-b-III tubulin (1:333,
Sigma-Aldrich), goat anti-doublecortin (DCX, 1:400, Santa Cruz
Biotechnologies, Santa Cruz, USA), mouse anti-rat CD-68 (ED-1,
1:200, AbD Serotec MorphoSys AbD, Du ¨sseldorf, Germany),
rabbit anti-GFAP (1:500, DakoCytomation, Glostrup, Denmark),
mouse anti-GFAP (1:400, Sigma-Aldrich), mouse anti-human
nucleus (HuNu, 1:100, Chemicon, Temecula, USA), rabbit anti-
Ki67 (1:500, Abcam, Cambridge, USA), rabbit anti-human nestin
(1:500, Chemicon). Primary antibodies were detected using
appropriate fluorescent Cy3 (Jackson ImmunoResearch Labora-
tories, West Grove, USA) or biotin-conjugated (Vector Laborato-
ries, Burlingame, USA) secondary antibodies (1:200), which were
then detected with Alexa 488-conjugated streptavidin (1:200,
Molecular Probes). In order to determine the specificity of the
primary antibodies and the level of background generated from
the secondary antibodies, in one well per in vitro-staining the
primary antibodies were omitted as negative control. For double
labeling, only one biotinylated secondary antibody was used at a
time. For nuclear staining Hoechst 33342 (1:1000, Invitrogen,
Carlsbad, USA) was added during final incubation with secondary
antibodies. Sections were mounted on PLL-coated slides (Thermo
Fisher Scientific, Waltham, USA) and slides were coverslipped
with glycerol-based mounting medium. Immunostainings were
19F MRI of Human Neural Stem Cells
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activities verified with a confocal laser scanning (Leica TCS SP2,
Leica Microsystems) microscope equipped with a supplementary
CCD camera (Leica Microsystems).
MRI data processing and statistical analysis
All MR images were processed with the program ImageJ
(http://rsbweb.nih.gov/ij/).
For SNR analysis of the
19F signal, the measured signal and
noise in the raw
19F images were corrected voxel-wise for non-
Gaussian noise distribution due to the low SNR [22]. Only voxels
with a corrected SNR above 3.5 were considered significant and
included in the analysis.
For display purposes of the merged
1H/
19F images, the fluorine
SNR datasets were resized to a 1286128 matrix with bilinear
interpolation, grey-levels were converted to transparency levels of
red, and overlaid on the
1H image.
To estimate the minimum number of cells (Nmin) per voxel to
generate a detectable SNR of 3.5, we assumed a linear correlation
between number of cells and SNR. Knowing the summed SNR of
all voxels (SNRtotal) with significant
19F signal and the overall
number of cells (Ntotal) within this volume the detection limit was
then calculated with the simple relationship Nmin=N total63.5/
SNRtotal, similar to a method described previously [11].
Differences between in vitro labeled and non-labeled cells were
evaluated with Student’s unpaired t-test. Data are expressed as
mean6SEM and differences considered significant at p,0.05.
Results
Labeling of NSCs
NSCs readily took up the PFPE emulsion without the aid of
transfection agents. The intracellular
19F content was maximized
for 100 mL of the
19F marker substance per mL medium as
confirmed with MRS (Fig. 1, A–C). With this protocol labeled cells
contained on average 3.7060.78*10
12 (n=3 biological replicates)
19F spins.
In order to analyze if the cells keep the fluorine marker over
time, we took out 1/3 of the cells (i.e. 1/3 of the internalized
19F)
directly after the labeling procedure and determined the amount
of intracellular
19F with MRS. The remaining 2/3 of the cells were
replated for another 7 days. The incorporated
19F was then again
measured and 2.1060.54 times (n=4 technical replicates) the
amount of the first sample was found, which is in good agreement
with the expected value of 2 in case there was no significant loss of
label.
The measured relaxation times were T1/T2=(280620) ms/
(15364) ms for the free PFPE marker and T1/T2=(38064) ms/
(6863) ms for the labeled cells.
Detectability and quantification in vitro
MRI of a dilution series of labeled NSCs (20,000, 10,000, 5,000
labeled and 65,000 non-labeled cells for control) suspended in
gelatin clearly detected spots with 20,000 down to 10,000 cells,
while there was no background
19F signal from non-labeled cells.
Figure 1. Optimization of labeling and in vitro detection limits. A–C:
19F MRS of NSCs incubated with 15 mL (A), 50 mL (B), and 100 mL (C) PFPE
emulsion per mL medium together with a KF solution as an internal standard, KF frequency set to 2120.9 ppm, main PFPE peak at 293.2 ppm, signal
intensity in arbitrary units. The cell signal was maximized at a concentration of 100 mL/mL. D–F: MRI of 20,000, 10,000, and 5,000 labeled, and 65,000
control cells plated in gelatin, D shows the merged
1H and
19F, E the
19F image only. The 20,000 and 10,000 cells spots were clearly detectable,
whereas a significant signal was not detected for the 5,000 cells, probably due to cells spreading over many voxels, thus not exceeding the critical
detection limit. From the summed SNR of the two spots with
19F signal we estimate that approximately 1,000 cells need to accumulate in one image
voxel to overcome the detection limit, as indicated by the crossing of the linear fit in F with the dashed line illustrating an SNR of 3.5. For the fit we
assumed 0 SNR for 0 cells. Error bars in F are over n=3 technical replicates. Note: The surface coil was adjusted parallel to the paper plane.
doi:10.1371/journal.pone.0029040.g001
19F MRI of Human Neural Stem Cells
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the SNR of the two cell clusters with significant signal
(SNRtotal=112614, n=3 technical replicates) we estimate that
the minimum number of cells, which need to accumulate in one
image voxel in order to generate significant signal in vitro,i s
approximately Nmin<1,000 cells (Fig. 1, D–F). This finding was
supported by
19F MRI of a dilution series of the
19F marker
(supplementary Fig. S1). Although the 5,000 cell spot is clearly
above the estimated detectable number of cells, it was most likely
not discovered because cells were spread over too many image
voxels.
Effect of the
19F marker in vitro
The labeling procedure had only very minor effects on the cells’
viability and no significant effects on their proliferation (Fig. 2, A–
H) and differentiation (Fig. 2, I–P) capacity. Furthermore, carefully
analyzing both the proportion and morphology of nestin+, GFAP+
and b-III tubulin+ cells, we did not detect any significant changes
compared to the non-labeled control cells. Also, no differences in
the numbers of Ki67+ cells were found either during proliferation
(37.763.2%; directly after the labeling) or after 7 days of
differentiation (27.261.0%) in vitro compared to non-labeled
control cells (44.162.4% for non-differentiated and 29.261.7%
for differentiated cells, n=3 technical replicates) (Fig. 2, Q).
The percentage of living cells was equal compared to controls
before labeling (95.264.2% and 94.765.0%) but significantly
decreased directly after incubation with the
19F marker
(83.163.7% compared to 92.966.6% for unlabeled cells,
p,0.05). However, this value normalized again after replating
and subsequent culturing of the cells for 7 days (87.065.6% for the
labeled cells and 88.963.2% for controls, n=3 biological
replicates, Fig. 2, R).
19F signal detectability in vivo
In order to assess whether
19F MRI is a useful tool for the
longitudinal tracking of implanted cells in the brain, we injected
PFPE labeled NSCs and non-labeled control cells into the striatum
of mice and scanned the animals a few days later. We detected
significant
19F signal from the grafts with labeled cells in all
animals, while there was no signal from implanted non-labeled
control cells (Fig. 3, A). Presence of Hoechst+/hunu+ cells allowed
definite assignment of NSC aggregations on histological sections
(Fig. 3, B, D, and F). These cell spots corresponded well, both in
intensity and location, to regions exhibiting significant
19F signal.
In the two mice with labeled cells grafted on both hemispheres, the
19F signal persisted at least 6 days after implantation (Fig. 3, C and
E). Quantitative SNR analysis of these animals revealed that total
19F SNR decreased by <20% from day 2 to day 6.
Figure 2. Effect of the labeling on cell viability, proliferation, and differentiation capacity. Photomicrographs of in vitro samples stained
for Ki67 (A, B, I and J), nestin (C, F E and H), GFAP (D, E G, H, K and N), and bIII-tubulin (L, M, O and P). There were no major qualitative differences in
the viability or proliferation and differentiation capacity of the labeled (B, F, G, H, J, N, O and P) versus non-labeled control cells (A, C, D, E, I, K, L and
M), both during proliferation (A–H), i.e. directly after the labeling procedure, and after 9 days of differentiation (I–P). The percentage of proliferating
Ki67+ cells during proliferation or after differentiation was not significantly altered by the labeling (Q). Quantification of the number of living cells
before, 0 days after, and 7 days after incubation with the
19F marker revealed that the viability was significantly decreased compared to controls at 0
days but normalized at 7 days after labeling (R). The scale bar represents 25 mm for M and P, 50 mm for all others.
doi:10.1371/journal.pone.0029040.g002
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surgery, the overall
19F SNR in all animals was determined
(SNRtotal=612.5) and used together with the known number of
transplanted cells (Ntotal=1.5 million) to calculate the minimum
number of detectable cells at an SNR=3.5 (Nmin<9,000).
Effect of the
19F marker in vivo
At the end of the
19F MRI in vivo measurements, the animals
were sacrificed and the brains were processed for immunohisto-
chemistry to study implanted cell phenotypes. Qualitative analysis
of brain sections stained for nestin, GFAP and DCX showed that
Figure 3. In vivo
19F MRI and correlation with immunohistochemistry.
1H,
19F, and merged MR images of a mouse (Animal 1), which had
been injected with non-labeled control cells into the left striatum and labeled NSCs into the right hemisphere (A). Only the labeled cells generated a
19F signal whereas hunu staining confirmed the presence of cell grafts on both sides as indicated by the arrows (B). MRI of another mouse (Animal 2)
2 days (C) and 6 days (E) after grafting showed no major signal loss in the
19F images over time. This animal had received two deposits of labeled cells
in the left striatum and one deposit in the right striatum. The location and intensity of
19F signal from cell clusters, marked with white arrows,
correlated well with hunu staining on histological sections. Note that the
19F resolution allows the distinction of the two clusters on the left
hemisphere (B, F). Only cells that were clearly immunoreactive to both hoechst and hunu were considered as grafted human NSCs (D). Scale bars are
50 mm for D, 1 mm for all others.
doi:10.1371/journal.pone.0029040.g003
19F MRI of Human Neural Stem Cells
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cells (Fig. 4 A–D). We also detected a portion of the implanted cells
that had already differentiated into DCX+ neuroblasts (Fig. 4 E
and F). Overall, these images revealed that the fraction of cells of
each cell phenotype studied was similar for
19F labeled and non-
labeled cell grafts.
Discussion
We show that efficient labeling of NSCs with a PFC-based
marker is possible without impairment of their naı ¨ve cell behavior
and thus, in consequence, their therapeutic potential. We have
successfully demonstrated detectability of these human neural stem
cells with high sensitivity after implantation into mouse brain and
the usefulness of this imaging approach for monitoring the cell
dynamics longitudinally because the graft was followed with
19F
MRI for a week, being most likely detectable even much longer.
Efficacy and effects of labeling NSCs with
19F
PFC nano-emulsions are particularly suitable agents for stem
cell tracking because of the excellent MR properties for imaging
and the high biocompatibility [10,23]. Important for a possible
clinical translation, PFCs are chemically stable, biologically inert,
and related compounds have already been evaluated in preclinical
and clinical trials as blood-substitutes [23,24,25].
Our labeling procedure with PFPE lead to an uptake of
3.7*10
12 spins/cell, similar to reports on other cell types. For
experimental studies,
19F uptake could potentially be further
Figure 4. Effect of the
19F marker on cell phenotypes in vivo. Photomicrographs of non-labeled control (A, C, E) and PFPE labeled NSCs (B, D, F)
on tissue sections from transplanted animals. The majority of the implanted cells were, at this early time point after injection, still neural stem and
progenitor cells as confirmed by nestin/hunu and GFAP/hunu stainings (A–D). Presence of DCX+/hunu+ (E, F) neuroblasts showed that NSCs were
capable of neuronal differentiation. By qualitative analysis we did not detect major differences in the PFPE labeled cell population compared to
control cells. Scale bars are 20 mm.
doi:10.1371/journal.pone.0029040.g004
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these are not approved for use in the clinic [10]. We found a high
T2/T1 ratio both for the free PFPE tracer and for the labeled cells.
This indicates that the MR properties of the tracer are in deed
optimal in terms of maximizing the SNR particularly when using
turbo spin echo sequences. We note however, that the reported
relaxation times may not be universal, e.g. due to slice thinning or
excitation/refocusing flip angle imperfections and echo train signal
variations.
Careful assessment of important immunohistochemical markers
revealed that the label has only minor effects on viability,
differentiation capacity, and proliferation in vitro and in vivo.I n
other reports the viability of PFC labeled stem cells was not
different from non-labeled controls [11,20] whereas we observed a
decrease in viability directly after incubation. This could either be
a specific feature of the human NSCs or be due to the relatively
high concentration of
19F marker in the medium compared to
those other studies. We observed a decrease in viability over time,
although non-significant, also in the non-labeled control cells. This
suggests that the impairment in viability may rather be related to
other factors such as the PolyHEMA coating of flasks.
The use of a fluorescent agent, attached to the PFPE, could
provide a more direct proof that the agent is internalized,
analyzing localization by fluorescence microscopy. However, most
fluorophores are not suitable for clinical use and, therefore, we
used an emulsion without fluorescent tag. We included thorough
washing steps in all procedures in order to remove excessive
19F
marker particles. Moreover, a study with a similar, fluorescent
PFC emulsion showed localization of the
19F marker in the cytosol
of murine neural progenitor cells and persistence of
19F MRI
signal over 2 weeks [20]. Importantly, we did not detect a decrease
in MRS-determined
19F content from labeled, replated cells over a
period of one week. In vivo the
19F SNR only slightly decreased
between day 2 and day 6 after implantation. Overall, there is
strong evidence that NSCs retain the label over time and can be
tracked longitudinally, even for longer periods than the time span
of this study. This feature of long-term tracking of cells was not
provided employing alternative fluorine markers such as Poly-L-
lysine CF3, for which labeled cells lost half the
19F signal within 7
days [26,27]. However, thorough long-term evaluations of both
effects of PFCs on grafted stem cells and efficacy of the labeled
cells in the pathological brain e.g. stroke models are needed in the
future.
Cell quantification and detection limits
The
19F MR signal is proportional to the amount of
magnetically equivalent fluorine nuclei within a certain voxel.
This allows quantification of the number of cells. If the total
number of implanted cells is known, one strategy is to link this
number to the sum total of SNR and to assume linear correlation
between both. This way each SNR can be assigned a cell number.
We employed this for the determination of detection limits by
extrapolation of the number of cells generating an SNR of 3.5.
However, the strategy works only under the assumption that cells
are labeled homogeneously, do not lose the label, and do not
proliferate as this leads to a dilution of
19F content/cell, and that
partial volume effects can be neglected. The assumption of a
homogeneous labeling is reasonable when fluorine content per cell
is averaged over a few hundred cells. Further, we have shown
containment of the
19F marker within NSCs over one week under
in vitro conditions. The dilution of label through cell division is a
potential threat to our strategy, since injected cells can divide after
transplantation. However, the cells used here cease to proliferate
shortly after implantation. The previously reported time span of 2
days for proliferation in vivo is rather short considering a doubling
time of approximately 72 hours under ideal in vitro conditions
[18,19,28,29].
With the small graft sizes used in brain implantation studies, an
image voxel is typically only partly filled by labeled cells. This
becomes particularly severe with
19F MRI as one strategy to
enhance sensitivity is to measure with rather low spatial resolution
[10]. As a consequence, quantification in regions with cell densities
below the detection limit leads to underestimated cell numbers,
graft borders are only inaccurately defined on
19F MR images, and
migratory processes on a small scale cannot be monitored. A post-
processing scheme to ease the problem has been applied in models
of T-cell homing to the pancreas or lymph node by dilation of
regions of interest by one-half voxel [12,13]. This scheme could
potentially be included in future MRI studies of
19F labeled NSCs
depending on expected cell distribution. In order to minimize
these partial volume effects in the first place, we used a relatively
high in vivo resolution (160 nL voxel size in the present report
compared to for example 305 nL used before in the mouse brain
[20]). To our knowledge there is only one in vivo study with a
higher resolution, but in mouse hind limb (15.6 nL voxel size
[30]). To compensate the loss of sensitivity at the higher resolution,
we decided for the use of surface radiofrequency coils with
inhomogeneous field profile and T2-weighted turbo spin echo
pulse sequences. Thus the measured
19F signal from a certain
region depended not only on the amount of fluorine contained
therein but also on
19F relaxation times and the region’s distance
from the coil. The use of time-consuming, purely spin-density
weighted pulse sequences can improve quantification only at the
cost of SNR per unit time. A volume coil with more uniform
magnetic field profile may be better suited for quantification.
However, the coil is often larger and less sensitive compared to a
surface coil. To minimize the problem we adjusted the setup in a
way that the cell spots were placed within the same distance from
the coil for the in vitro experiments. For the in vivo experiments cells
were spread over a slightly larger region and further away from the
coil, thereby leading to loss of signal. This may partly explain the
order of magnitude difference of in vitro and in vivo detection limits.
In conclusion, coil design and choice of pulse sequence must be
carefully adapted to the specific application in future studies
employing
19F MRI for cell tracking.
Using a
19F marker with high spin density, using optimized
radiofrequency coils and a very high field of 11.7 T we show
detection of small numbers of cells in a preclinical setting. Our
data indicates that within ,1 h acquisition time in vitro detection of
,1,000 cells/voxel is feasible corresponding to less than 10
16
fluorine spins/voxel. In vivo we estimate a detection limit in the
order of ,10,000 cells/voxel. The limits are in agreement with
earlier studies [11,12,14]. These numbers are usually sufficient for
imaging the graft core and possibly even for larger cell clusters
migrating away from injection sites in the brain.
Potential of
19F MRI of NSCs in cell replacement therapy
The usefulness of cell tracking with
19F MRI mainly depends on
its sensitivity. Although the
19F marker and MRI methods used in
this study are likely to be safe for clinical translation, detection
sensitivity will be orders of magnitude lower in a clinical setting
due to lower field strengths, larger radiofrequency coils, and
shorter acquisition times [31]. Still,
19F MRI of NSCs may become
clinically relevant in the near future as a result of further advances
in MRI hardware and pulse sequence development.
However, before stem cell based therapy of neurological
disorders can be used in human patients the action of these cells
needs to be further investigated in animal models [16].
19F labeling
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nanoparticles in such preclinical investigations particularly when
the pathology induces changes in
1H relaxation times that make
distinction between diseased tissue and labeled cells difficult.
Possible scenarios include vasogenic edema after ischemic stroke
or lesions involving bleedings, in which heterogeneous background
T1,T 2, and T2* impose major challenges in unambiguous
detection of magnetically labeled cells with
1H MRI. As
19F
MRI allows quantification of cell numbers it may also help to
optimize efficacy of stem cell therapy e.g. in terms of injection sites,
monitoring graft size changes [29] and routes of migration.
Conclusion
In future clinical applications, NSCs are one of the most
potential and attractive cell sources for stem cell based treatment
of diseases affecting the central nervous system. However, for the
successful translation of cell therapy additional live imaging
tools such as MRI are a prerequisite.
19F MRI is a promising,
quantitative, and non-invasive technique to monitor NSC grafts
after implantation. We have shown that labeling NSCs with a PFC
marker, potentially suitable for clinical use, does not significantly
impair cell function both in vitro and in vivo. Our high detection
sensitivity and resolution have allowed for the first time true in vivo
tracking of small groups of human NSCs. This is particularly
interesting for studies of brain cell replacement therapy, in which
the graft can initially be small and may become further diluted
through lesion-induced cell migration.
Supporting Information
Figure S1 Dilution series of
19F marker.
19F MRI of six
tubes containing different concentrations of the PFPE agent (1, 2,
3, 4, 5, and 6 times 31.1 mM corresponding to multiples of 3*10
15
19F spins/voxel). The tube with 3*10
15 spins/voxel can clearly be
depicted (SNR,6). Assuming a labeling efficacy of 3–4*10
12
spins/cell this would translate to detection of less than 1,000 cells/
voxel in agreement with the results obtained with our quantifica-
tion strategy (Fig. 1). Pulse sequence parameters were chosen
identical to the cell dilution series in Fig. 1. Note: The surface coil
was oriented parallel to the paper plane.
(TIF)
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